New intra-renal graft genes associated with tolerance or rejection  by McMorrow, Isabel M. et al.
Kidney International, Vol. 61, Symposium 1 (2002), pp. S85–S93
New intra-renal graft genes associated with tolerance
or rejection
ISABEL M. MCMORROW, KAVITHA NARAYAN, DAVID H. SACHS, and CHRISTIAN LEGUERN
Transplantation Biology Research Center, Massachusetts General Hospital/Harvard Medical School, Boston,
Massachusetts 02129, USA
New intra-renal graft genes associated with tolerance or rejection. plants in humans [3]. We have previously demonstrated
Background. Recipient type mononuclear cells infiltrating that graft infiltrating cells (GILs) in accepted kidneys
kidney allografts have different phenotypes and functions ac- are phenotypically and functionally distinct from thosecording to the fate of the graft. We hypothesized that different
present in the rejected graft [4, 5]. Recent analysis ofgenetic programs were involved in rejected or accepted tissues
the T cell receptor repertoire of GILs also confirmedand thus, transcripts that correlated with the clinical status could
be identified by a differential expression strategy. This strat- the selectivity of the intra-graft cell subsets (Note added
egy was applied to miniature swine class II matched, class I in proof). Collectively, these results suggested that the
disparate kidney grafts, which are accepted in recipient animals microenvironment of the graft could affect either thetreated for 12 days with Cyclosporin A (CsA).
progression of rejection or the development of tolerance.Methods. The mRNA differential display RT-PCR tech-
In this view, it is conceivable that different genetic pro-nique (DDRT-PCR) was used to detect clinical status-specific
transcripts. cDNA templates for this analysis were derived from grams are utilized by subsets of GILs entering a kidney
biopsies of accepted (CsA treated) and rejected (untreated) undergoing rejection or in the process of being accepted.
kidney grafts 8 days post-transplantation.
Several reports have shown differential expression be-Results. A first screening procedure identified 23 PCR prod-
tween rejector and tolerant GILs genes for adhesionucts differentially amplified in either tolerant or rejector sam-
ples. Nucleotide sequence of these partial transcripts showed molecules [6], cytokines [7, 8], chemokines [9, 10], and
that 11 out of 23 (48%) sequences had unknown open reading their respective receptors [9, 11]. However, no definitive
frames while 12 had substantial homology to known sequences. correlation has been established between the presence
To validate the approach, rejection-associated (RA) cDNA 1
of these molecules and the clinical status of the graft(RA-1) was characterized further. The results indicated that
because of the wide cellular distribution of these recep-RA-1 is the porcine equivalent of secreted protein acidic and
rich in cysteine (SPARC). Expression studies demonstrated tors [7, 12–14] and the pleitropic effects of their ligands
that upregulation of SPARC gene transcription preceded other [7, 12, 13].
indicators of kidney dysfunction and correlated with the extent An earlier attempt to elucidate rejection-specific genes
of graft infiltration.
was performed in rat cardiac allografts by differential dis-Conclusion. DDRT-PCR appears to be a powerful tech-
play RT-PCR (DDRT-PCR) and defined five genes ofnique to identify genes differentially expressed in grafted tis-
sues that correlate with tolerance or rejection. One of the gene potential importance [15]. However, the clinical rele-
transcripts identified through this method, SPARC, may be a vance of that discovery remains questionable since the
reliable marker of tissue injury consequent to cellular infiltra- subtractive partners for the differential display were re-tion and rejection.
jected and syngeneic “accepted” grafts, respectively. The
lack of information on key genes that, for example, may
INTRODUCTION direct local T cell inactivation in accepted transplants or
tissue repair in kidneys undergoing rejection episodes,Immune tolerance to major histocompatibility com-
has prompted the present search for new genes. To iden-plex (MHC) class I disparate, class II-matched kidney
tify potential key molecules/genes differentially activatedgrafts can be reproducibly achieved in miniature swine
in either condition, we have opted for the very sensitivefollowing a 12 day course of CsA [1, 2]. This transplanta-
DDRT-PCR technique with modifications to accommo-tion model is reproducible and consistent with retrospec-
date our clinically relevant model. Using a stringent screen-tive findings illustrating similar trends for renal trans-
ing procedure to eliminate false positive signals and the
overwhelming abundance of conserved/dominant mRNA,
Key words: transplantation, differential display, SPARC. we report the identification of 10 rejection-associated (RA)
and 13 tolerance-associated (TA) partial transcripts de- 2002 by the International Society of Nephrology
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tected in the renal microenvironment. In addition, we plification of cDNA Ends (Life Technologies, Inc., Rock-
ville, MD) according to the manufacturer’s directions.have fully characterized one RA transcript that appears
to be an indicator of cellular infiltration and has poten- cDNA was made from 1 g of total RNA from a rejected
renal biopsy at POD 7 (animal 11444) with the genetial to become a clinical marker to survey tissue damage/
remodeling. specific antisense primer 5-GTTACAGCTAAGAATG
TCATGAC-3. A nested gene specific antisense primer
5-CTGCTCCTTGATGCCGAAGC-3; was used to ex-
MATERIALS AND METHODS
tend the remaining 5 sequence of porcine SPARC. Se-
Isolation of total RNA and generation of cDNA quence data were subjected to BLAST search to identify
homology with known genes.Renal biopsy samples from a tolerant animal (11560)
on post-operative day (POD) 8 and a rejecting animal
RT-PCR Analysis of renal biopsies(11444) on POD 7 were analyzed. At the time of biopsy,
the samples were immediately frozen in guanidinium cDNA was prepared from 1 g of total RNA as pre-
viously described using the oligo dT primer provided in(4 M guanidine thiocyanate, 0.5% Sarkosyl, 25 mM so-
dium citrate) and total RNA was prepared as previously the kit. For the SPARC PCR reaction, 1 l of first strand
cDNA was amplified with the sense 5-GCCTGGATCTdescribed [5, 16]. First strand cDNA synthesis was per-
formed using a modified degenerate oligo-dT primer TCTTCCTCCT-3; and antisense 5-CCTCTCGTACA
AGGTGACCA-3 primers. The reaction consisted of 1(222: T12VC, V  G, A or C [15]), 0.5 g of total RNA
and the Superscript II cDNA Synthesis kit (Life Technol- buffer A (Fisher Scientific Co., Pittsburgh, PA), 1 M
of each primer, 80 M each dNTP and 2.5 U Taq poly-ogies, Inc., Rockville, MD).
merase (Fisher Scientific Co., Pittsburgh, PA) in a final
Differential display PCR volume of 50 l. Amplification conditions included 25
cycles of 94C for 30 seconds, 55C for 30 seconds andDifferential mRNA display was carried out as pre-
viously described [15, 17] with the exception that 1  Ci 72C for 45 seconds followed by 10 minutes at 72C. The
GAPDH RT-PCR reactions were done under the same32P dATP (3000 Ci/mmol, DuPont/NEN Co., Boston,
MA) was used to label each PCR reaction. Bands of conditions with the sense 5-GGATTTGGTCGTATTG
GGC-3; and antisense 5-TGAGCTTGACAAAGTGGinterest were excised from the gel and placed in 200 l
of elution buffer (500 mM ammonium acetate, 10 mM TCG-3 primers for 30 cycles of amplification. The CD2
PCR was for 30 cycles with the following sense 5-GGGmagnesium acetate, 1 mM EDTA) to elute the DNA.
AATTCGGAGAAAWGRTGARGAGC-3 and anti-
RNA slot blot and analysis: sense 5-GGGATCCTCTGCTGGTGARCYTGTG
TGC-3 primers. The intensity of the signals was deter-Total RNA from the same renal biopsy samples that
served as the template for the differential mRNA display mined by computer assisted densitometry (Molecular
Analyst, Bio-Rad, Hercules, CA) and were corrected forwas loaded on a slot blot (2.5 g RNA/slot). In addition,
RNA from a naı¨ve kidney (animal 12806) was loaded as the relative quantity of cDNA template using the signal
obtained from the GAPDH RT-PCR. Expression indexa control. In order to normalize for the amount of RNA
loaded, the slot blot was probed with a GAPDH probe. (E. I.) was calculated as described [5]. The SPARC E.I.
for the POD 0 sample was subtracted from the values
Labeling of PCR products and probing slot blot of all subsequent biopsies to evaluate possible changes
in SPARC expression post-transplantation.PCR products were labeled by PCR in a reaction con-
sisting of 1 buffer A (Fisher Scientific Co., Pittsburgh,
PA), 1 M of each primer, 4 M each dNTP, 50  Ci
RESULTS32P dATP (3000 Ci/mmol), 50  Ci 32P dCTP (3000
Detection of differentially expressedCi/mmol, DuPont/NEN Co., Boston, MA) and 2.5 U of
intra-kidney transcriptsTaq polymerase (Fisher Scientific Co., Pittsburgh, PA)
in a final volume of 50 l. The PCR cycle conditions In order to identify key molecules involved in the
intra-graft mechanisms that stimulate or curtail alloreac-were forty cycles of 94C for 15 seconds, 40C for 60
seconds and 72C for 20 seconds. Slot blots were probed tivity of infiltrating cells, a comparison of the transcrip-
tional status of renal biopsies from accepted and rejectedand quantitated as previously described [5].
renal grafts was undertaken. Based on our previous data
Cloning and sequencing of the PCR products showing clear divergence in the phenotype of GILS from
accepted and rejected grafts at early time points post-PCR products were first cloned into the pCR-Blunt
plasmid (Invitrogen Corp., Carlsbad, CA) and then se- transplantation, a first screening was performed with
POD 7 and eight renal biopsy samples [4, 5]. Quantitativequenced. The remaining 5 sequence of porcine SPARC
was obtained using the 5 RACE System for Rapid Am- and qualitative evaluations of transcripts were obtained
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slot-blots (step 3, Fig. 1) containing RNA from naı¨ve,
accepted and rejected kidney grafts as illustrated in Fig-
ure 2B. In this example, the data indicated that the RA-1
cDNA fragment hybridized preferentially to RNA from
the rejected graft suggesting that the RA-1 transcript is
dominant in this type of sample. In the primary screen-
ing, a total of 35 distinct bands were excised from the
analytical gel and were labeled to probe RNA slot blots;
17 of these (49%) showed consistent differential binding
by slot-blot analysis. The PCR products were designated
rejection associated (RA) or tolerance associated (TA)
genes according to their preferential binding ability and
were sequenced for further identification. Some of the
PCR products contained multiple bands of similar sizes
that were cloned individually, resulting in a total of 23
distinct transcripts (Table 1). Eleven PCR product se-
quences out of 23 (48%) corresponded to open reading
frames (ORFs) that have not yet been identified. Of the
remaining 12 partial transcripts, there were two dupli-
cates RA-4 and RA-5 with high homology to the MHC
class II-associated invariant chain and ten with substan-
tial similarity to known sequences.
Molecular characterization of the
RA-1/SPARC transcript
Fig. 1. Schematic of the protocol developed for generation and screen-
In order to determine the potential applicability ofing of differential display RT-PCR products. The first level of screening
(1) involved an oligo dT primer to select for expressed transcripts, the approach, complete characterization of one RA
the second (2) depended upon the reproducibility of products in two cDNA was carried out. The initial 646 bp RA-1 cDNA
independent PCR reactions while in the third (3), a RNA slot blot was
obtained from the sequencing gel was selected for furtherprobed to evaluate the relative expression of each transcript in naı¨ve,
tolerant and rejected kidneys. characterization because of its high sequence homology
with the secreted protein acidic and rich in cysteine
(SPARC) which has been implicated in numerous tissue
remodeling processes [18] as well as in tumor metastasis
using the differential mRNA display RT-PCR technique [19]. The full-length RA-1 cDNA was obtained by 5
(DDRT-PCR). Since this technology has been shown to RACE technology. Sequence analysis showed a 900 nu-
generate high levels of false positives, a stringent screen- cleotide ORF embedded in an 1190 nucleotide long
ing procedure was applied that included restricted am- cDNA. Comparison of the deduced porcine RA-1 amino
plification of mRNA with poly dT primer, selection of acid sequence with the bovine, murine, rat and human
amplified bands that were reproducibly present on se- SPARC sequences demonstrated a high degree of con-
quencing gels and use of the selected material to probe served residues with 96, 92, 91, and 92% similarity, re-
RNA from relevant tissue samples (rejected and ac- spectively (Fig. 3). Similarly, high nucleotide sequence
cepted kidney grafts). homology was found with SPARC homologs from nu-
Figure 1 presents a diagram of the entire procedure, merous species, confirming the initial identification of
which was performed with biopsies from either an ac- RA-1 as porcine SPARC (data not shown). The tissue-
cepted graft from animal 11560 at POD8 or from a graft distribution of the porcine SPARC gene expression was
undergoing rejection from animal 11444 at POD7. Fig- assessed by Northern blot analysis and demonstrated a
ure 2A shows a typical pattern of gel bands generated high level of transcription in brain cells, but low levels of
from rejected (R) or tolerant (T) grafts amplified using expression in all other normal tissues, including kidney,
a single primer pair. The band identified as RA-1 was spleen, lymph nodes, liver and thymus (data not shown).
seen reproducibly in two separate amplifications from In contrast, SPARC mRNA was not detected by North-
independent cDNA preparations from the same RNA ern analysis in naı¨ve or activated peripheral blood lym-
(results not shown). The selected band was then eluted phocytes (PBL) or in GILS from a rejected kidney (data
from the gel, amplified by PCR, and labeled to be used as not shown), a feature consistent with previous results
a radioactive probe. Additional specificity tests involved obtained with human and murine SPARC [20]. The fact
that active SPARC gene transcription was detected in or-hybridization of the 32P-labeled PCR product to RNA
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Fig. 2. Identification of RA-1. (A) Autora-
diograph of DD RT-PCR products amplified
from rejected (R) or tolerated (T) renal allo-
grafts with same primer set. (B) Slot blot of
total RNA from naı¨ve, accepted and rejected
renal grafts probed with RA-1 PCR product.
Table 1. Differentially expressed cDNAs of endogenous SPARC mRNA in normal renal tissues
implying that any quantitative variation of mRNA levelsPCR product Kidney PBMC Sequence homology
in grafted organs could be readily detected. The timeRA-1   SPARCa
RA-2   Clusterin course of SPARC expression in graft biopsies of animals
RA-3   Profilin treated (Tolerant) or untreated (Rejector) with a short
RA-4 NDb ND Invariant chain (class II)
course of CsA was, therefore, evaluated and comparedRA-5 ND ND Invariant chain (class II)
RA-6 ND ND tmp 83.5 motif with a standard method of monitoring kidney function by
RA-7 ND ND IL-2 receptor motif plasma creatinine levels (Fig. 4 A–E). Rejector animalsRA-8 ND ND ORF?c
11444 and 12719 had elevated creatinine levels by PODRA-9a ND ND ORF?c
RA-9b ND ND ORF?c 7 which correlated with a concomitant rise of SPARC
TA-1   WC1 mRNA as detected by RT-PCR analysis (Fig. 4 A and B).TA-2a   ORF?
Interestingly, a clear upregulation in SPARC expressionTA-2b ND ND ORF?
TA-3a ND ND ORF? was detectable by POD 4 in the graft from animal 11444,
TA-3b ND ND ORF? suggesting that the RT-PCR detection was a more sensi-TA-3c ND ND ORF?
tive means of monitoring the viability of grafted tissueTA-4   ORF?
TA-5 ND ND Olfactory receptor motif than the measurement of serum creatinine levels (Fig. 4A).
TA-6a ND ND Epsilon globin motif
However, confirmation of this trend in the second re-TA-6b ND ND ORF?
TA-7 ND ND rRNA? jected graft (Fig. 4B) was precluded by poor quality RNA
TA-8a ND ND ORF? obtained from the biopsies on PODs 2 and 4.
TA-8b ND ND Ca release channel motif
In contrast to the rejected grafts, accepted kidneys
a75% nucleotide homology necessary for identification
from animals 11560, 11561 and 13544 produced low levelsb Not done
c Open reading frame but no obvious homology to known sequences of SPARC transcript throughout the early post-operative
period between PODs 1 and 15 (Fig. 4 C, D, E). Signifi-
cant increases in SPARC gene transcription were ob-
served at PODs 18 and 28 in the graft of animal 11560gans undergoing rejection, while the PBL were SPARC-
(Fig. 4C) and POD 34 for animal 13544 (Fig. 4E). Thenegative, suggested that the SPARC mRNA originated from
upregulation of SPARC at these time points appearedkidney cells and not from graft infiltrating lymphocytes.
to correlate with pathological findings of moderate acute
Temporal expression of SPARC in renal transplants cellular rejection and chronic changes consistent with
tissue damage (data not shown).A semi-quantitative RT-PCR assay was developed to
monitor the time course of SPARC mRNA transcription
Factors influencing SPARC gene expression infollowing kidney transplantation (Materials and Meth-
renal graftsods). This approach was first tested on normal porcine ana-
As the SPARC molecule has been shown to be a ge-tomic samples and the results demonstrated a SPARC
neric marker of tissue damage (reviewed in 18), thegene transcription profile consistent with that observed
upregulation that has been observed in our transplanta-by Northern blot analysis (data not shown). In particular,
this more sensitive technique confirmed the low levels tion model could be the consequence of ischemia, surgi-
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Fig. 3. Alignment of RA-1 with SPARC. Full
length deduced amino acid sequence of RA-1
aligned with bovine, murine, rat and human
SPARC.
cal trauma or the nephrotoxic effects of CsA [21]. To tested in a second kidney graft, MHC-matched to the
first kidney, that was accepted long-term without CsAdetermine whether any of these factors were the cause
of SPARC gene expression, renal biopsies from a control treatment. As shown in Figure 4G, there was a rapid
increase in SPARC expression along with a correspond-animal that underwent a sham renal transplant along
with CsA treatment (13234) were subjected to SPARC ing rise in serum creatinine immediately after trans-
plantation of the second kidney. As this increase inRT-PCR analysis (Fig. 4F). The absence of SPARC gene
transcription during the first eight days post-transplant SPARC expression occurred in the absence of CsA treat-
ment and correlated with the time course of the creati-suggested that neither ischemia nor surgical trauma was
a major factor in the upregulation of SPARC. Due to nine level, it would appear that CsA was not a major
factor in SPARC upregulation.the premature death of the animal at POD12, it was
however, not possible to assess the long-term effects of GILs of recipient origin enter both the accepted and
rejected kidneys. In the rejected kidney, however, thisCsA in this case. The potential effects of the drug on
the control of SPARC gene expression were, therefore, influx is approximately 4-fold greater and peaks earlier
McMorrow et al: Intra-renal graft genes in transplantationS-90
Fig. 4. Time course of SPARC expression
and creatinine level in: A, B) rejected renal
allografts; C, D, E ) tolerant renal allografts;
F) control animal that underwent a sham renal
transplant and was treated with CsA G tolerant
animal that received a second kidney matched
to the first in the absence of CsA treatment.
SPARC expression (gray bars) was compared
to the serum creatinine level (line) as a mea-
sure of kidney function and an indirect indica-
tor of rejection. Animal numbers are indicated.
at PODs 7–9 as compared with 12–18 in the tolerated produced in transplanted kidneys from recipient animals
treated or untreated with a tolerance inducing protocol.graft [22]. To determine whether the entry of GILs into
In the initial screening performed on POD 7–8 biopsies,the graft caused the tissue injury and, thereby, the eleva-
17 cDNA fragments had reproducible and marked differ-tion of SPARC mRNA, biopsy samples from a represen-
ences in signal intensity between the rejected and ac-tative pair of accepted and rejected kidneys were evalu-
cepted samples. Further nucleotide sequence determina-ated to determine the extent of graft infiltration by a
tion of these cDNA fragments showed that 50% of thesequantitative RT-PCR for infiltrate-specific CD2 mRNA
corresponded to previously described sequences whereas(Fig. 5). In the rejected sample 11444, the extent of
the other half had ORFs with no homology to previouslyrecipient cell infiltration coincided with an increase in
known genes (Table 1). Ten of these cDNAs were prefer-SPARC expression. Conversely, the right panel of Fig-
entially expressed in rejected kidney grafts and were calledure 5 shows that in the accepted graft, no such correlation
rejection-associated (RA) transcripts to distinguish themwas apparent. These observations, which were confirmed
from tolerance-associated (TA) mRNA which comprisedin another pair of biopsies, suggested that the early infil-
the rest of the list (Table 1). Given that differential screen-tration of GILs in rejected kidneys was one of the causes
ing techniques are always subject to artifacts [23] andof the upregulation of SPARC gene expression.
that several molecules have previously been described
in transplants [6–10, 12–14], the adequacy of the ap-
DISCUSSION proach used in our study as well as the nature and poten-
The present report describes a technical approach to tial function(s) of the new open reading frames discov-
ered may be questioned.the identification of transcripts that were differentially
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Fig. 5. Time course of SPARC expression and graft infiltration in a rejected and accepted graft. SPARC expression (black bars) and graft
infiltration (gray bars, as measured by CD2) in representative rejected and accepted kidneys.
The RNA display RT-PCR-based technique employed sent the first successful identification of intragraft genes
in our study [15, 17] is notorious for generating artifactual differentially regulated according to the clinical status
data, mainly due to the low annealing specificity of the of the transplant in a pre-clinical large animal model.
degenerate primers in combination with the high sensi- Most of the RA and TA genes of known origin appear
tivity of detection (reviewed in [24]). Several improve- to have a function relevant to the clinical status of the
ments have been suggested to overcome these difficulties type of graft in which they were discovered. For example,
including the use of more specific primers tailored to the detection of fragments of transcripts for structural
mRNA amplification [25, 26] as well as selective amplifi- proteins such as clusterin (RA-2), profilin (RA-3) and
cation of minor mRNA templates [27]. To reduce the SPARC (RA-1) correlated with the clinical status of a
number of false positives, we opted for a stringent proce- graft undergoing rejection (Table 1). Likewise, rejected
dure that included: (1) multiple highly resolved acryl- organs contained infiltrates predominantly composed of
amide gel separations of independently amplified PCR activated T cells [28], and thus the presence of signals
products from the same RNA templates to test for repro- for the IL-2 receptor motif (RA-7) and class II associated
ducibility; (2) probing of RNA from normal, rejected invariant chain (RA-4 and 5) was expected. Relevance
and accepted kidneys to document differential expres- to the induction of tolerance was also found in some of
sion; and (3) sequencing of selected PCR fragments to the transcripts identified in accepted kidneys. Among
eliminate transcripts previously described in other trans- these, the TA-8b, TA-5, and TA-1 sequences appear to
plantation models. The application of such screening
be promising as they have homology to membrane struc-
procedures to our model appeared to be efficient since,
tures or motifs that have been identified in signal trans-of the 35 bands initially selected from the gel, 17 (49%)
duction systems [29–31]. The detection of additionalcorresponded to cDNAs which were differentially ex-
PCR-products from the same POD 7–8 biopsy samplespressed in the two types of grafts tested. Aside from the
with a similar experimental design may be ineffective dueRA-4 and RA-5 PCR products, which corresponded to
to the presence of “dominant” mRNA sequences that werethe same region of the MHC class II associated invariant
amplified in the first screening. Alternative approaches tochain (Table 1), the sequences of the other amplified
overcome this problem may include the elimination of pre-products were unique. A similar approach was used pre-
ponderant transcripts before selective RT-PCR amplifi-viously to describe five genes associated with rejection
cation [27] and/or the addition of a hybridization step us-in a rat heart transplant model [15]. The clinical rele-
ing the sequences reported in Table 1 to eliminate cDNAsvance of these results appears limited, however, as they
that have already been identified. The use of biopsieswere obtained in a rodent model. More importantly,
from different post-operative days, preferably in the timethese latter studies used syngeneic grafts, rather than
frame of rejection (PODs 9–15 in this model) [1, 2], mayallogeneic transplants from tolerance-conditioned recipi-
also allow the detection of other transcripts that wereents as “accepted” reference samples in the differential
display. Consequently, we believe that our results repre- not differentially expressed at PODs 7 and 8.
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